Search
Aldafermin
go.drugbank.com/drugs/DB16086InvestigationalStudy in Subjects With Nonalcoholic Steatohepatitis and Stage 2/3 Fibrosis (ALPINE 2/3)). … Aldafermin is under investigation in clinical trial NCT03912532 (Evaluation of Efficacy, Safety and Tolerability of Aldafermin in a Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-center
Synonyms: (phe5>met,ser6>arg,ala8>ser,gly9>ser,his11>leu) fibroblast growth factor 19 (human fgf19) (5-194)-peptide, produced in escherichia coliAmtolmetin guacil
go.drugbank.com/drugs/DB16088InvestigationalCategories: Heterocyclic Compounds, 1-RingBaicalein
go.drugbank.com/drugs/DB16101InvestigationalBaicalein is under investigation in clinical trial NCT03830684 (A Randomized, Double-blind, Placebo-controlled, Multicenter and Phase ⅡA Clinical Trial for the Effectiveness and Safety of Baicalein Tablets
Categories: Heterocyclic Compounds, 1-Ring, Heterocyclic Compounds, 2-RingBemarituzumab
go.drugbank.com/drugs/DB16105InvestigationalBemarituzumab is under investigation in clinical trial NCT03694522 (A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (Mfolfox6) in Gastric/gastroesophageal Junction Cancer (FIGHT)).
Centhaquine
go.drugbank.com/drugs/DB16122InvestigationalCenthaquine is under investigation in clinical trial NCT04045327 (Efficacy of PMZ-2010 (Centhaquine) a Resuscitative Agent for Hypovolemic Shock).
Categories: Heterocyclic Compounds, 1-RingCeralifimod
go.drugbank.com/drugs/DB16123InvestigationalCeralifimod is under investigation in clinical trial NCT01226745 (Phase 2 Extension Trial in Patients With Relapsing-remitting Multiple Sclerosis (RRMS)).
Categories: Heterocyclic Compounds, 1-Ring, Sphingosine 1 Phosphate Receptor ModulatorsChiauranib
go.drugbank.com/drugs/DB16124InvestigationalChiauranib is under investigation in clinical trial NCT03974243 (Chiauranib in Combination With Chidamide in Patients With Relapsed/refractory Non-hodgkin's Lymphoma).
Categories: Heterocyclic Compounds, 2-RingCinaciguat
go.drugbank.com/drugs/DB16126InvestigationalCinaciguat is under investigation in clinical trial NCT01067859 (A Phase Iib Study to Investigate the Efficacy and Tolerability of Lower Doses Cinaciguat (25 ΜG/h, 10 ΜG/h) Given Intravenously to Patients
Crovalimab
go.drugbank.com/drugs/DB16128ApprovedInvestigationalCrovalimab is a humanized monoclonal antibody and complement C5 inhibitor.[L50908] It consists of two heavy chains (451 amino acid residues each) and two light chains (217 amino acid residues each). … [L50933] Unlike other complement inhibitors previously approved for PNH, crovalimab uses a mechanism called anti-C5 sequential monoclonal antibody recycling technology that allows the drug to bind to
Synonyms: IGHJ4*01 (100%)) (9.8.15) (1-123)-HOMO SAPIENS IGHG1*, IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENS C5 (COMPLEMENT 5)), MONOCLONAL ANTIBODYGAMMA1 HEAVY CHAIN (1-451) (VH (VICUGNA PACOS IGHV3S1*01 (70.4%)/HOMO SAPIENS IGHV3-66*01 (69.4%)-(IGHD)-HOMO SAPIENSDiflomotecan
go.drugbank.com/drugs/DB16138InvestigationalDiflomotecan is under investigation in clinical trial NCT00080015 (Diflomotecan (BN80915) Administered Once Every 3 Weeks in Treating Patients With Sensitive Small Cell Lung Cancer (SCLC)).